Bli medlem
Bli medlem

Du är här


Adaptimmune Therapeutics plc: Adaptimmune Announces New Research and Development Facility in Oxfordshire

'Enterprise Zone' Building Will House Company's Expanding R&D OperationOXFORD, UK and PHILADELPHIA, Oct. 06, 2015 (GLOBE NEWSWIRE) -- Adaptimmune
Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical
stage biopharmaceutical company focused on the use of T-cell therapy to treat
cancer, today announced plans to expand its research and development
operation into a major new purpose-built facility at Milton Park,

Construction of Adaptimmune's 67,000 square foot 'Enterprise Zone' building is
already under way following a traditional groundbreaking ceremony. The
flagship facility will provide laboratory space with associated offices,
meeting rooms and a café area to accommodate a team of around 200
highly-skilled research and development specialists.

The new building is designed to support the Company's continuing growth of its
research and development operation and is scheduled for delivery in late

Adaptimmune has signed a 25-year agreement with break options to lease the
building from developer MEPC, which owns Milton Park, one of Europe's largest
business parks and home to over 7,500 employees and 250 organizations.

"We are delighted to be working closely with MEPC on this exciting new
building, which will provide best-in-class laboratories to support the
expansion of our R&D team and enable continuing progress with our research
programs," said James Noble, Chief Executive Officer of Adaptimmune.

"We started up Adaptimmune as three people on Milton Park in 2008 to research
into engineered T-cell receptors to fight cancer, and we now have over 150
staff from across the world working out of our U.K. and U.S. facilities. They
are contributing substantial scientific, development and corporate expertise
to progress our preclinical and clinical programs and accelerate the
development of our internal pipeline. All share a common aim of wanting to
bring breakthrough treatments to cancer patients."

Following its foundation in the U.K., Adaptimmune launched its U.S operation
in 2011 after a longstanding research collaboration with the University of
Pennsylvania. The Company has rapidly expanded its clinical programs and is
currently running five Phase I/II trials in multiple cancers across the U.S.
targeting the NY-ESO-1 cancer antigen in both solid and hematologic cancers
with promising early results. Adaptimmune also has an IND open with its
second therapeutic candidate, MAGE-A10, and a third candidate in planning for
IND submission in 2016.

In May 2015, the Company achieved a successful IPO on NASDAQ, generating net
proceeds in excess of $176 million, and is advancing a pipeline of
therapeutic candidates based on its proprietary T-cell engineering platform.

"This is great news for both Adaptimmune and the continuing development of
Oxfordshire's thriving biotech industry and economy," said James Dipple,
Chief Executive Officer, MEPC Milton Park.

"Adaptimmune was established at Milton Park in 2008 in a small laboratory, and
we have watched this pioneering company expand into a globally recognized
business. We are delighted that we are able to accommodate their growth plans
by building a bespoke, state of the art new building."

Nicholas Hare is the architect for the new building, which is part of the Park
Drive Central scheme at Milton Park.


Images are available from Margaret Henry, Adaptimmune

1. CGICGI of the new Adaptimmune building (illustrative only)

2. Photo: Breaking ground for Adaptimmune's new R&D building, Oxfordshire.

L-R: Adrian Rawcliffe (CFO, Adaptimmune) - Philip Campbell (Commercial
Director, MEPC) - Dr Helen Tayton-Martin (COO, Adaptimmune) - James Dipple
(CEO, MEPC) - James Noble (CEO, Adaptimmune) and Paul Pavia (Head of
Development, MEPC).

About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor platform.
Established in 2008, the Company aims to utilize the body's own machinery -
the T-cell - to target and destroy cancer cells by using engineered,
increased affinity T-cell receptors (TCRs) as a means of strengthening
natural patient T-cell responses. Adaptimmune's lead program is an affinity
enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR
therapeutic candidate has demonstrated signs of efficacy and tolerability in
Phase 1/2 trials in solid tumors and in hematologic cancer types. As of June
30, 2015, 85 patients had been treated with Adaptimmune's NY-ESO TCR
therapeutic: 47 under Adaptimmune's IND, and 38 under a National Cancer
Institute IND. In June 2014, Adaptimmune announced that it had entered into a
strategic collaboration and licensing agreement with GlaxoSmithKline for the
development and commercialization of the NY-ESO TCR program. The Company
currently has over 150 employees. For more

About Milton Park
Milton Park is home to 7,500 people and 250 organizations. As one of Europe's
largest business parks, Milton Park accommodates all types of business, from
manufacturing and medical services to mobile technology. MEPC is the manager
and developer of Milton Park.

About MEPC Limited
MEPC provides, creates and develops the right buildings and working
environments for modern organisations, helping companies grow, succeed and
belong to vibrant business communities. By investing in long term
relationship with customers, MEPC understands the ever changing needs of
business and delivers property solutions that are fit for purpose.

The business estates managed by MEPC accommodate over 350 organizations and
circa 10,000 people working in manufacturing, professional services, and
leading edge science and technology. The on-site teams consistently exceed
expectations through their professionalism, dedication and approachability.
Investors benefit from this unique approach to working with occupiers which
produces consistent class leading returns. For more information:

Forward-Looking Statements
This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
which statements may be identified by words such as "believe," "may", "will,"
"estimate," "continue," "anticipate," "intend," "expect" and other words of
similar meaning.
These forward-looking statements involve certain risks and uncertainties. Such
risks and uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development
activities and clinical trials; our ability to submit an IND and successfully
advance our technology platform to improve the safety and effectiveness of
our existing TCR therapeutic candidates; the rate and degree of market
acceptance of T-cell therapy generally and of our TCR therapeutic candidates;
government regulation and approval, including, but not limited to, the
expected regulatory approval timelines for TCR therapeutic candidates; and
our ability to protect our proprietary technology and enforce our
intellectual property rights; amongst others. For a further description of
the risks and uncertainties that could cause our actual results to differ
materially from those expressed in these forward-looking statements, as well
as risks relating to our business in general, we refer you to our final
Prospectus filed with the Securities and Exchange Commission on May 7, 2015.
We urge you to consider these factors carefully in evaluating the
forward-looking statements herein and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in their
entirety by this cautionary statement. The forward-looking statements
contained in this press release speak only as of the date the statements were
made and we do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances. We intend that all
forward-looking statements be subject to the safe-harbor provisions of the

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T: (215) 966-6264

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.